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Human T-cell leukemia virus type 1 (HTLV-1) infects approximately 20 million people worldwide and 
5% of them may develop adult T-cell leukemia (ATL), a fatal T-cell malignancy with no effective 
treatment currently available. The homologous HTLV-2 does not cause ATL, but is associated with 
milder neurologic disorders. Both viruses encode a potent viral oncoprotein, termed Tax, which 
deregulates several cellular pathways, including NF-κB. In addition to Tax, the HTLV-1 proviral 
genome encodes from the antisense strand, a basic leucin zipper factor, HBZ, which plays an 
essential role in the oncogenic process leading to ATL. Comparative studies of the functional activity 
of Tax-1 and HBZ, and the HTLV-2 homologous, Tax-2 and APH-2 (HTLV-2 antisense protein), may 
provide clues to explain the dissimilar pathobiology of HTLVs. Herein, we compared the effect of the 
viral regulatory proteins HBZ and APH-2 on Tax-modulated NF-κB cell signaling. Our data 
demonstrated that APH-2 suppressed, more efficiently than HBZ, the Tax-dependent NF-ĸB 
activation. By confocal microscopy, we observed that, differently from HBZ, the APH-2 protein is 
recruited into cytoplasmic structures where co-localized with Tax. The co-expression of APH-2 and 
Tax impaired the degradation of the NF-ĸB inhibitor IκB-α, restraining the transcriptional factor p65 
into the cytoplasm. APH-2, but not HBZ, was present in complex containing the TRAF3 protein, an 
upstream inhibitor of the alternative NF-κB pathway. Applying the CRISPR/Cas9 technique, we 
generated TRAF3 knock-out cell lines. Several TRAF3-/- clones were selected and NF-κB promoter 
activity was analyzed by luciferase assays. The results showed that, in absence of induction, the NF-
κB promoter is slightly activated, in the TRAF3-/- cell line compared to the parental cell line. The 
absence of TRAF3 adaptor factor did not inhibit the Tax-mediated NF-κB activation. Ongoing studies 
using TRAF3-/- clones will allow to clarify the effect of the HTLV antisense protein on the alternative 
NF-κB pathway activation. 
 
